Chimeric Therapeutics makes headway with its CLTX CAR T therapy; what next?

Source: Mark_Kostich, Shutterstock


  • Chimeric Therapeutics is progressing well with its Phase 1 CLTX CAR T trial at City of Hope.
  • CLTX CAR T can potentially address the high unmet medical need for recurrent glioblastoma (GBM), given the unique properties demonstrated in preclinical studies.
  • Chimeric is focused on rapid progression towards the registration trial for recurrent GBM.
  • The Company is also assessing the initiation of a Phase 1 basket trial for colorectal cancer, melanoma, prostate cancer, sarcomas, and small cell lung cancer.

Chimeric Therapeutics Limited (ASX:CHM) is a clinical-stage cell therapy company centred around encouraging Chlorotoxin (CLTX) CAR T technology from City of Hope (COH). Currently, the Company is conducting a Phase 1 clinical trial of CLTX CAR T at COH.

CLTX CAR T therapy: first in class

In 2020, CHM licensed the exclusive worldwide rights of CLTX CAR T cell therapy developed at COH Cancer Centre.

CLTX CAR T has an extended life, with a composition of matter intellectual property (IP) profile which expires in 2036. CLTX CAR T utilises Chlorotoxin, a 36-amino acid peptide derived from the toxin of deathstalker scorpion, as its tumour targeting domain.

Image source: CHM Investor Presentation, 18 March 2021

CLTX has a proven human safety profile as it has been employed as an imaging agent. The fact that CLTX can bind to a range of tumours is quite promising and indicates significant therapeutic potential in several solid tumours.

Because of the unique properties demonstrated in preclinical studies, CLTX CAR T has the potential to address the high unmet medical need for effective therapy against recurrent GBM (WHO grade III-IV).

DO READ: Using scorpion venom to treat tumours: A look at Chimeric Therapeutics' CLTX technology

CAR T Cell Therapy in a nutshell

Chimeric Antigen Receptor T (CAR T) Cell Therapy modifies patients’ immune cells (or T-cells) to use directly against their melanoma.

  • In CAR T, patients’ cells are engineered for receptor expression on the cell surface to recognise antigens of cancerous cells.
  • After the administration, CAR T cells identify the antigen targets on malignant cells. The CAR then binds to the cancerous cells.
  • Once CAR T cells bind to the malignant cells, they convey a signal to attack the cancer cells. One single CAR T cell can generate over 10,000 new cells to target and destroy the tumour cells.

Image source: CHM Investor Presentation, 18 March 2021

Increasing unmet medical need in GBM

Almost more than 300,000 patients worldwide are diagnosed with brain and nervous system cancer each year. Given the tremendous unmet medical need for glioblastoma, the new, innovative therapies could offer a valuable treatment for glioblastoma patients.

GBM is the most common and most lethal of brain and nervous system cancer with:

  • The median overall survival of nearly eight months for GBM patients.
  • Almost 5% of GBM patients survive five years.
  • Nearly 38% of patients with GBM survive one-year survival.
  • Only three FDA approved treatments and no standard of care in recurrent GBM.
  • Bevacizumab, the last FDA-approved therapy, did not exhibit overall survival benefit.

DID YOU KNOW: Chimeric Therapeutics (ASX:CHM) onboards new VP to boost oncology pipeline

Phase 1 CLTX CAR T Clinical Study in brief

The Company commenced the dosing of Phase 1 clinical trial in late September 2020 at City of Hope. The trial’s primary objective is to assess the safety of CLTX CAR T cells for patients having MMP2 recurrent GBM and to evaluate the maximum tolerated dose schedule and an advised dosing plan for Phase 2. Here are the details of the trial:

  • Approximately 18-36 patients with recurrent or progressive GBM.
  • Dose escalation of 44 X 106 to 440 X 106 CLTX CAR T cells.
  • CHM is examining two administration methods for the treatment-
    • Single route intratumoral delivery.
    • Dual-route intratumoral and intraventricular delivery.

Image source: CHM Investor Presentation, 18 March 2021

To Know More, Do Read: Chimeric Therapeutics’ (ASX:CHM) Phase 1 CLTX CAR T trial inches ahead

CHM anticipates expanding CLTX CAR T for additional tumours

Based on the available evidence for binding of CLTX in other solid tumours, Chimeric Therapeutics is currently exploring the initiation of a Phase 1 basket trial for colorectal cancer, melanoma, prostate cancer, sarcomas, and small cell lung cancer.

Image source: CHM Investor Presentation, 18 March 2021

Outlook: the way forward

Chimeric Therapeutics is focused on developing its product pipeline with ground-breaking cell therapies in the oncology space.

Chimeric Therapeutics’ plans for the upcoming period:

Image source: CHM Investor Presentation, 18 March 2021

On 14 April 2021, CHM shares were trading 5.172% higher at AU$0.305 (at AEST 03:34 PM).

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK